Dec. 27 2021
Eye drops that can eliminate the need for reading glasses or bifocals have been approved for patients – and an eye surgeon in Sioux Falls was instrumental in the process.
The FDA has approved Vuity prescription eye drops, a new treatment option for age-related presbyopia or blurred near vision requiring reading glasses or bifocals.
It is one of the most common eye conditions, starting for almost half of all Americans after 40 years.
Dr. Vance Thompson of Vance Thompson Vision was instrumental in bringing it to market, as the lead investigator in the FDA-controlled trial that led to patient approval.
“This whole project has fascinated me from the start,” Thompson said in a statement.
“What blew me away was knowing that pilocarpine, which is a central component of Vuity drops, was first invented in the late 1800s and used to treat glaucoma for over 100 years. . I think it is amazing that Allergan has researched taking traditional treatment with a high safety profile and using it for something new to benefit millions of patients. I am so honored that our team by Vance Thompson Vision has something to do with this introduction to the world.
Vuity works as early as 15 minutes and lasts up to six hours to improve near and intermediate vision without affecting distance vision. Specially designed for presbyopia, Vuity uses the eye’s own ability to reduce pupil size, creating a pinhole effect with the patient’s own pupil to increase depth of field and help people avoid need reading glasses. It is the first and only eye drops approved by the FDA for the treatment of presbyopia.
“Working with our patients during the clinical trial, I was surprised at how easy the drop regimen was and how quickly patients noticed improvement in their near vision,” said Dr. Jason Schmit of Vance Thompson Vision. “This treatment will help so many patients gain better near vision without the need for contact lenses or reading glasses.”